Physician profile
Gail Weissman
NPI 1295327229
$5,667.80
in general payments reported to CMS, 2019-2025
21 companies · $1,226 in 2025
The $1,226 reported for 2025 was more than what 86% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $328 · 2022: $556 · 2023: $812 · 2024: $2,747 · 2025: $1,226.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,239 · Education: $1,545.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,239.36 |
| Education | $1,544.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $1,704.67 | 2023-2024 | Vtama |
| Abbvie INC. | $983.59 | 2021-2025 | |
| Pfizer INC. | $532.71 | 2021-2025 | |
| Janssen Biotech, INC. | $461.16 | 2021-2025 | Tremfya |
| Ucb, INC. | $320.12 | 2024-2025 | Bimzelx |
| E.R. Squibb & Sons, L.L.C. | $313.17 | 2024-2025 | Sotyktu |
| Sun Pharmaceutical Industries INC. | $270.53 | 2021-2025 | Ilumya |
| Amgen INC. | $182.46 | 2023-2025 | Otezla |
| Incyte Corporation | $163.81 | 2021-2025 | Opzelura |
| Janssen Scientific Affairs, LLC | $108.29 | 2022 | |
| Genzyme Corporation | $101.45 | 2021-2025 | |
| Lilly USA, LLC | $72.76 | 2021-2025 | Ebglyss, Taltz, Olumiant |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $72.29 | 2024-2025 | Siliq, Duobrii |
| Galderma Laboratories, L.P. | $64.69 | 2024-2025 | |
| Arcutis Biotherapeutics, INC. | $62.38 | 2023-2025 | Zoryve |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $57.23 | 2021-2025 | Anzupgo, Adbry |
| Regeneron Healthcare Solutions, INC. | $56.89 | 2025 | Dupixent |
| Merz North America, INC. | $54.91 | 2024-2025 | |
| Organon LLC | $46.76 | 2025 | Vtama |
| Novartis Pharmaceuticals Corporation | $20.62 | 2025 | |
| Verrica Pharmaceuticals INC. | $17.31 | 2024 | Ycanth |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gail Weissman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.